Mounjaro
Mounjaro, a newly launched weight-loss and diabetes medicine, is now available in India. Originally developed by Eli Lilly for type 2 diabetes, it also claims to help users lose up to 20% of their body weight as a secondary benefit.
Mounjaro, a newly launched weight-loss and diabetes medicine, is now available in India. Originally developed by Eli Lilly for type 2 diabetes, it also claims to help users lose up to 20% of their body weight as a secondary benefit.
The cost of this medicine ranges from ₹3,500 for a 2.5 mg vial to ₹4,375 for a 5 mg vial. A patient in India may have to spend approximately $200 per month for a weekly 5 mg dose, subject to the doctor's prescription.
Pharma manufacturer Eli Lilly said it has launched a first-of-its-kind medication in India to treat obesity and type 2 diabetes, following approval from the Central Drugs Standard Control Organisation (CDSCO).
Following marketing authorization from the CDSCO, Mounjaro is now available in a single-dose vial for weekly injections, with its highest dose being 15 mg.
Mounjaro is classified as a GLP-1 receptor agonist but distinguishes itself by also targeting GIP receptors. This dual mechanism enhances blood sugar regulation and strengthens its appetite-suppressing effects, which means users feel fuller for longer, consume less, and ultimately lose weight.
Chemically known as Tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss, while in the U.S., it is marketed as Zepbound for obesity.
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.
Many users experience gastrointestinal discomfort, including symptoms such as nausea, vomiting, diarrhea, and constipation. These side effects are generally mild and tend to improve over time as the body adjusts to the medication.
Mounjaro is now available in India via select pharmacies and hospitals and is accessible only by prescription.
Ozempic (Semaglutide) is one of the most popular weight loss medicines in India. It is a potent medication for diabetes with notable weight-loss benefits, was originally approved for type 2 diabetes, and it has been found to help users reduce weight substantially as a secondary benefit.